MAIA Net Income Applicable To Common Shares from 2010 to 2026
| MAIA Stock | USD 1.94 0.47 19.50% |
Net Loss | First Reported 2010-12-31 | Previous Quarter -11.3 M | Current Value -11.8 M | Quarterly Volatility 2.8 M |
Check MAIA Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MAIA Biotechnology's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.7 M, Interest Expense of 48.74 or Selling General Administrative of 6.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 11.43. MAIA financial statements analysis is a perfect complement when working with MAIA Biotechnology Valuation or Volatility modules.
MAIA | Net Income Applicable To Common Shares | Build AI portfolio with MAIA Stock |
Analyzing MAIA Biotechnology's Net Income Applicable To Common Shares over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income Applicable To Common Shares has evolved provides context for assessing MAIA Biotechnology's current valuation and future prospects.
Latest MAIA Biotechnology's Net Income Applicable To Common Shares Growth Pattern
Below is the plot of the Net Income Applicable To Common Shares of MAIA Biotechnology over the last few years. It is the net income that remains after preferred dividends have been deducted, available to common shareholders. MAIA Biotechnology's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in MAIA Biotechnology's overall financial position and show how it may be relating to other accounts over time.
| Net Income Applicable To Common Shares | 10 Years Trend |
|
Net Income Applicable To Common Shares |
| Timeline |
MAIA Net Income Applicable To Common Shares Regression Statistics
| Arithmetic Mean | (8,508,803) | |
| Coefficient Of Variation | (33.04) | |
| Mean Deviation | 2,592,042 | |
| Median | (6,492,782) | |
| Standard Deviation | 2,811,393 | |
| Sample Variance | 7.9T | |
| Range | 6M | |
| R-Value | (0.81) | |
| Mean Square Error | 2.9T | |
| R-Squared | 0.66 | |
| Significance | 0.000076 | |
| Slope | (451,960) | |
| Total Sum of Squares | 126.5T |
MAIA Net Income Applicable To Common Shares History
About MAIA Biotechnology Financial Statements
MAIA Biotechnology stakeholders use historical fundamental indicators, such as MAIA Biotechnology's Net Income Applicable To Common Shares, to determine how well the company is positioned to perform in the future. Although MAIA Biotechnology investors may analyze each financial statement separately, they are all interrelated. For example, changes in MAIA Biotechnology's assets and liabilities are reflected in the revenues and expenses on MAIA Biotechnology's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in MAIA Biotechnology. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Loss | -11.3 M | -11.8 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether MAIA Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of MAIA Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Maia Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Maia Biotechnology Stock:Check out the analysis of MAIA Biotechnology Correlation against competitors. For information on how to trade MAIA Stock refer to our How to Trade MAIA Stock guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MAIA Biotechnology. Expected growth trajectory for MAIA significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive MAIA Biotechnology assessment requires weighing all these inputs, though not all factors influence outcomes equally.
MAIA Biotechnology's market price often diverges from its book value, the accounting figure shown on MAIA's balance sheet. Smart investors calculate MAIA Biotechnology's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since MAIA Biotechnology's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that MAIA Biotechnology's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether MAIA Biotechnology represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, MAIA Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.